Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland
Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of trials,...
Similar Items
-
Multifocal multisystem Langerhans cell histiocytosis
by: Anupam Das, et al.
Published: (2017-01-01) -
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN: DIAGNOSTIC MARKERS AND FEATURES OF PHARMACOTHERAPY
by: M.V. Кhaitovych, et al.
Published: (2021-03-01) -
Multisystem atrophy: clinical manifestations, pathogenesis questions
by: T. A. Valikova, et al.
Published: (2010-08-01) -
Critically ill infant with multisystem inflammatory syndrome related to COVID-19
by: Arturo A. Canul-Euan, et al.
Published: (2021-10-01) -
COVID-19-related Multisystem Inflammatory Syndrome in a Young Adult
by: Francisco Pombo, et al.
Published: (2021-04-01)